Although IMQ can induce both CD4 and CD8 T cell responses [16],[17], the induction of CD4 versus CD8 T cell responses in these two patients may be partly attributable to the differential effects of prior chemotherapy/bevacizumab on the function of antigen presenting cells [18] as well as differences in the complex tumor microenvironment [19]. This evidence concerns the gene CD8A and neoplasm.